Cargando…

Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults

Background: In adults aged ≥60 years, two doses of the herpes zoster subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01(B) Adjuvant System) elicited humoral and cell-mediated immune responses persisting for at least six years. We assessed immunogenicity nine years post...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, Tino F., Volpe, Stephanie, Catteau, Gregory, Chlibek, Roman, David, Marie Pierre, Richardus, Jan Hendrik, Lal, Himal, Oostvogels, Lidia, Pauksens, Karlis, Ravault, Stephanie, Rombo, Lars, Sonder, Gerard, Smetana, Jan, Heineman, Thomas, Bastidas, Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037441/
https://www.ncbi.nlm.nih.gov/pubmed/29461919
http://dx.doi.org/10.1080/21645515.2018.1442162
_version_ 1783338330375585792
author Schwarz, Tino F.
Volpe, Stephanie
Catteau, Gregory
Chlibek, Roman
David, Marie Pierre
Richardus, Jan Hendrik
Lal, Himal
Oostvogels, Lidia
Pauksens, Karlis
Ravault, Stephanie
Rombo, Lars
Sonder, Gerard
Smetana, Jan
Heineman, Thomas
Bastidas, Adriana
author_facet Schwarz, Tino F.
Volpe, Stephanie
Catteau, Gregory
Chlibek, Roman
David, Marie Pierre
Richardus, Jan Hendrik
Lal, Himal
Oostvogels, Lidia
Pauksens, Karlis
Ravault, Stephanie
Rombo, Lars
Sonder, Gerard
Smetana, Jan
Heineman, Thomas
Bastidas, Adriana
author_sort Schwarz, Tino F.
collection PubMed
description Background: In adults aged ≥60 years, two doses of the herpes zoster subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01(B) Adjuvant System) elicited humoral and cell-mediated immune responses persisting for at least six years. We assessed immunogenicity nine years post-initial vaccination. Methods: This open extension study (NCT02735915) followed 70 participants who received two HZ/su doses in the initial trial (NCT00434577). Blood samples to assess the cellular (intracellular cytokine staining) and humoral (ELISA) immunity were taken at year nine post-initial vaccination. Results: Participants' mean age at dose 1 was 72.3 years. The fold increases over pre-vaccination in the mean frequency of gE-specific CD4+ T-cells expressing ≥2 activation markers plateaued from year four post-dose 1 until year nine. Anti-gE antibody geometric mean concentrations plateaued and remained above pre-vaccination levels from year four onwards. Immunogenicity at year nine was similar across age strata (60–69, ≥70 years) and confirmed statistical prediction model results using data for up to year six. Further modeling using all data up to year nine predicted immune responses would remain above the pre-vaccination level up to year 15. Conclusion: In adults aged ≥60 years, HZ/su-induced immunogenicity remained above pre-vaccination levels for at least nine years post-initial vaccination. Summary: After vaccination with HZ/su, both cell mediated and humoral immunity remained above pre-vaccination levels up to year 9 regardless of age group. Immune responses are predicted to remain above baseline up to 15 years post initial vaccination.
format Online
Article
Text
id pubmed-6037441
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-60374412018-07-11 Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults Schwarz, Tino F. Volpe, Stephanie Catteau, Gregory Chlibek, Roman David, Marie Pierre Richardus, Jan Hendrik Lal, Himal Oostvogels, Lidia Pauksens, Karlis Ravault, Stephanie Rombo, Lars Sonder, Gerard Smetana, Jan Heineman, Thomas Bastidas, Adriana Hum Vaccin Immunother Research Paper Background: In adults aged ≥60 years, two doses of the herpes zoster subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01(B) Adjuvant System) elicited humoral and cell-mediated immune responses persisting for at least six years. We assessed immunogenicity nine years post-initial vaccination. Methods: This open extension study (NCT02735915) followed 70 participants who received two HZ/su doses in the initial trial (NCT00434577). Blood samples to assess the cellular (intracellular cytokine staining) and humoral (ELISA) immunity were taken at year nine post-initial vaccination. Results: Participants' mean age at dose 1 was 72.3 years. The fold increases over pre-vaccination in the mean frequency of gE-specific CD4+ T-cells expressing ≥2 activation markers plateaued from year four post-dose 1 until year nine. Anti-gE antibody geometric mean concentrations plateaued and remained above pre-vaccination levels from year four onwards. Immunogenicity at year nine was similar across age strata (60–69, ≥70 years) and confirmed statistical prediction model results using data for up to year six. Further modeling using all data up to year nine predicted immune responses would remain above the pre-vaccination level up to year 15. Conclusion: In adults aged ≥60 years, HZ/su-induced immunogenicity remained above pre-vaccination levels for at least nine years post-initial vaccination. Summary: After vaccination with HZ/su, both cell mediated and humoral immunity remained above pre-vaccination levels up to year 9 regardless of age group. Immune responses are predicted to remain above baseline up to 15 years post initial vaccination. Taylor & Francis 2018-03-21 /pmc/articles/PMC6037441/ /pubmed/29461919 http://dx.doi.org/10.1080/21645515.2018.1442162 Text en © 2018 GalxoSmithKline Biologicals SA. Published with license by Taylor & Francis http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Schwarz, Tino F.
Volpe, Stephanie
Catteau, Gregory
Chlibek, Roman
David, Marie Pierre
Richardus, Jan Hendrik
Lal, Himal
Oostvogels, Lidia
Pauksens, Karlis
Ravault, Stephanie
Rombo, Lars
Sonder, Gerard
Smetana, Jan
Heineman, Thomas
Bastidas, Adriana
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
title Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
title_full Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
title_fullStr Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
title_full_unstemmed Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
title_short Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
title_sort persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037441/
https://www.ncbi.nlm.nih.gov/pubmed/29461919
http://dx.doi.org/10.1080/21645515.2018.1442162
work_keys_str_mv AT schwarztinof persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT volpestephanie persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT catteaugregory persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT chlibekroman persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT davidmariepierre persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT richardusjanhendrik persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT lalhimal persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT oostvogelslidia persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT pauksenskarlis persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT ravaultstephanie persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT rombolars persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT sondergerard persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT smetanajan persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT heinemanthomas persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults
AT bastidasadriana persistenceofimmuneresponsetoanadjuvantedvaricellazostervirussubunitvaccineforuptoyearnineinolderadults